secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sionna Therapeutics, Inc. (SION)
CIK:        0002036042
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001628280-25-049246
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sionna Q3 net loss $20.3M; starts Phase 2a trial for SION-719; cash runway into 2028
--------------------------------------------------------------------------------

- Net loss of $20.3M in Q3 2025 versus $25.4M in Q3 2024; R&D expenses fell to $16.0M from $24.6M due to prior year license charge.
- Cash and equivalents totaled $325.0M as of Sep 30, 2025, expected to fund operations into 2028.
- Initiated PreciSION CF Phase 2a proof-of-concept trial for SION-719 as add-on to standard of care in cystic fibrosis; topline data expected in mid-2026.
- Initiated Phase 1 trial evaluating SION-451 in proprietary dual combinations with CFTR correctors SION-2222 and SION-109; topline data mid-2026.
- Appointed Caroline Stark Beer as Chief Business Officer in September 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2036042/000162828025049246/0001628280-25-049246-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2036042/000162828025049246/sion-20251105.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-049246

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer